May 01, 2023 / 02:00AM GMT
Presentation
May 01, 2023 / 02:00AM GMT
=====================
Corporate Participants
=====================
* Hiromitsu Ikeda
Astellas Pharma Inc. - Corporate Head of Advocacy & Relations
* Jotaro Suzuki
Astellas Pharma Inc. - VP and Primary Focus Lead of Blindness & Regeneration
* Naoki Okamura
Astellas Pharma Inc. - President, CEO,CFO & Director
=====================
Conference Call Participants
=====================
* Akinori Ueda
Goldman Sachs Group, Inc., Research Division - Equity Analyst
* Hidemaru Yamaguchi
Citigroup Inc., Research Division - Research Analyst
* Kasumi Haruta
Crédit Suisse AG, Research Division - Research Analyst
* Kazuaki Hashiguchi
Daiwa Securities Co. Ltd., Research Division - Research Analyst
* Madoka Sato
Schroders plc - Analyst
* Seiji Wakao
JPMorgan Chase & Co, Research Division - VP
* Shinichiro Muraoka
Morgan Stanley, Research Division - Research Analyst
* Shinya Tsuzuki
Astellas Pharma Inc
(OTCPK:ALPMY)
$
13.73
-0.69 (-4.79%)
Market Cap: 24.60 Bil
Enterprise Value: 26.29 Bil
PE Ratio: 12.80
PB Ratio: 2.21
GF Score: 81/100 Astellas Pharma Inc to Acquire IVERIC bio Inc M&A Presentation Transcript
May 01, 2023 / 02:00AM GMT
Release Date Price:
$15.26
(+1.60%)
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot